


S Figure 1


S figure 1 . atRA enhances total Foxp3+ cells in CD4+ but not in CD8+ cell populations. 2×10^5 CD4+CD62L+CD25-Foxp3-(GFP-) or 2×10^5 CD8+CD62L+CD25-Foxp3-(GFP-) cells isolated from C57BL/6 Foxp3gfp reporter mice were stimulated with immobilized anti-CD3 (1 $\mu g/ml$), soluble anti-CD28 (1 $\mu g/ml$), IL-2 (100 U/ml) \pm TGF- β (2 ng/ml), and with (CD4_{TGF β +atRA} or CD8_{TGF β +atRA}) or without atRA (50nM) (CD4_{TGF $\beta}+atRA</sub> or CD8_{TGF<math display="inline">\beta$ +atRA}) or without atRA (50nM) (CD4_{TGF $\beta}+atRA</sub> or CD8_{TGF<math display="inline">\beta$ +atRA}). The data are summary of three independent experiments showing the total cell number of Foxp3+ and Foxp3- cells from TGF- β -primed CD4+ or CD8+ cells (x 10^6) , * p<0.05, ** p<0.01, *** p<0.001, NS, no significance.</sub></sub>


S Figure 2




S Figure 2. atRA enahces Foxp3 mRNA expression on TGF-β-primed CD4+ but not on TGF-β-primed CD8+ cells. The cells were isolated and cultured as s Figure 1. The expression of Foxp3 mRNA was determined by quantitative RT-PCR on various CD4+ and CD8+ cells activated with TCR \pm TGF-β \pm atRA. Data are Mean \pm SEM of three separate experiments. * p<0.05.


S Figure 3





S Figure 3. Both CD4+ and CD8+ cells similarly express RAR α protein. Naïve or activated CD4+ and CD8+ cells that had been stimulated with TCR \pm TGF- β for three days were subjected to Western blot analysis for atRA receptor α chain (RAR α) and β -Actin. The levels of RAR α were normalized to β -Actin, with the ratio of naïve CD4+ cells being arbitrarily assigned a value of 1. The results shown are representative of the 3 independent experiments (top) and summary of three experiments (mean \pm SEM) (bottom).





S Figure 4. Addition of atRA enhances the suppressive ability of TGFB primed CD4+ but not CD8+ cells against IFN-y production of T responder cells. Naïve CD4+ or CD8+ cells were co-cultured with soluble anti-CD3(1 ug/ml), anti-CD8 (1 ug/ml), anti-IL-4 (5 ug/ml), rm-IL-12 (10 ng/ml), APC, in the presence of 1:1, 1:2, 1:4 ratios of $CD4_{TGEB}$, $CD4_{TGFB+atRA}$ or $CD8_{TGFB}$, $CD8_{TGFB+atRA}$. Cells were stimulated at day3, then harvested and restimulated with PMA (0.25 mg/ml) and ionomycin (0.25 mg/ml) for 1 hr, then together with brefeldin A (5 mg/ml) for another 4 hours. IFN-y+ cells on the gate of CD8 or CD4 was determined by FACS staining. Left are representative and right are value of three separate experiments.